Daniel Kottmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Daniel Kottmann has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Frank McCaughan
Department of Medicine, University of Cambridge, Cambridge, UK
2 shared publications Wenrui Guo
Victor Phillip Dahdaleh Heart and Lung Research Institute, Department of Medicine, University of Cambridge, Cambridge, UK
2 shared publications- Adam Grundhoff
Department of Viral Genomics, Leibniz Institute of Virology, Hamburg, Germany
1 shared publication - Alan Lau
Bioscience, Oncology R&D, AstraZeneca, Cambridge, United Kingdom
1 shared publication Alexandra Müller
Institute for Neuropathology Medical Center – University of Freiburg Faculty of Medicine University of Freiburg Freiburg Germany
1 shared publicationAndreas Hlinak
Berlin‐Brandenburg State Laboratory Frankfurt (Oder) Germany
1 shared publication
Latest Publications
- Open Access
- 12 December 2025
- Published by Springer Nature in Communications Chemistry
- Vol. 8 (1)
Utilising multi-modal data-driven network analysis to identify monotherapy and combinational therapy targets in SOX2-dependent squamous cell lung cancer
Drug discovery requires understanding disease mechanisms, making the integration of multi-modal data essential. These data types, including omics, disease-associated, and pathway information, must be combined to uncover therapeutic insights. We developed iPANDDA, a computational pipeline that integrates these data through a network-based approach to predict candidate drug targets for specific diseases. We applied iPANDDA to lung squamous cell carcinoma (LUSC), a subtype of non-small cell lung cancer representing ~25% of global cases. Despite advances in cancer therapeutics, targeted treatments for LUSC remain limited, partly due to a lack of robust models to study carcinogenesis and therapeutic response. The SOX2 gene, amplified in ~50% of patients, plays a critical role in sustaining the cancer phenotype. Using iPANDDA, we identified and validated SOX2-dependent therapeutic targets. In vitro inhibition studies confirmed AKT and mTOR complexes as key monotherapy and combination therapy targets and revealed pathways for SOX2-targeted combination therapies.
- 12 December 2025
- Published by Springer Nature in Communications Chemistry
- Vol. 8 (1)
Open AccessUtilising multi-modal data-driven network analysis to identify monotherapy and combinational therapy targets in SOX2-dependent squamous cell lung cancer
Drug discovery requires understanding disease mechanisms, making the integration of multi-modal data essential. These data types, including omics, disease-associated, and pathway information, must be combined to uncover therapeutic insights. We developed iPANDDA, a computational pipeline that integrates these data through a network-based approach to predict candidate drug targets for specific diseases. We applied iPANDDA to lung squamous cell carcinoma (LUSC), a subtype of non-small cell lung cancer representing ~25% of global cases. Despite advances in cancer therapeutics, targeted treatments for LUSC remain limited, partly due to a lack of robust models to study carcinogenesis and therapeutic response. The SOX2 gene, amplified in ~50% of patients, plays a critical role in sustaining the cancer phenotype. Using iPANDDA, we identified and validated SOX2-dependent therapeutic targets. In vitro inhibition studies confirmed AKT and mTOR complexes as key monotherapy and combination therapy targets and revealed pathways for SOX2-targeted combination therapies.
- Open Access
- 31 October 2021
- Published by Wiley in Molecular Oncology
- Vol. 16 (2) , 527-537
Early assessment of circulating tumor DNA after curative‐intent resection predicts tumor recurrence in early‐stage and locally advanced non‐small‐cell lung cancer
Circulating tumor DNA (ctDNA) has demonstrated great potential as a noninvasive biomarker to assess minimal residual disease (MRD) and profile tumor genotypes in patients with non‐small‐cell lung cancer (NSCLC). However, little is known about its dynamics during and after tumor resection, or its potential for predicting clinical outcomes. Here, we applied a targeted‐capture high‐throughput sequencing approach to profile ctDNA at various disease milestones and assessed its predictive value in patients with early‐stage and locally advanced NSCLC. We prospectively enrolled 33 consecutive patients with stage IA to IIIB NSCLC undergoing curative‐intent tumor resection (median follow‐up: 26.2 months). From 21 patients, we serially collected 96 plasma samples before surgery, during surgery, 1–2 weeks postsurgery, and during follow‐up. Deep next‐generation sequencing using unique molecular identifiers was performed to identify and quantify tumor‐specific mutations in ctDNA. Twelve patients (57%) had detectable mutations in ctDNA before tumor resection. Both ctDNA detection rates and ctDNA concentrations were significantly higher in plasma obtained during surgery compared with presurgical specimens (57% versus 19% ctDNA detection rate, and 12.47 versus 6.64 ng·mL −1 , respectively). Four patients (19%) remained ctDNA‐positive at 1–2 weeks after surgery, with all of them (100%) experiencing disease progression at later time points. In contrast, only 4 out of 12 ctDNA‐negative patients (33%) after surgery experienced relapse during follow‐up. Positive ctDNA in early postoperative plasma samples was associated with shorter progression‐free survival ( P = 0.013) and overall survival ( P = 0.004). Our findings suggest that, in early‐stage and locally advanced NSCLC, intraoperative plasma sampling results in high ctDNA detection rates and that ctDNA positivity early after resection identifies patients at risk for relapse.
- 31 October 2021
- Published by Wiley in Molecular Oncology
- Vol. 16 (2) , 527-537
Open AccessEarly assessment of circulating tumor DNA after curative‐intent resection predicts tumor recurrence in early‐stage and locally advanced non‐small‐cell lung cancer
Circulating tumor DNA (ctDNA) has demonstrated great potential as a noninvasive biomarker to assess minimal residual disease (MRD) and profile tumor genotypes in patients with non‐small‐cell lung cancer (NSCLC). However, little is known about its dynamics during and after tumor resection, or its potential for predicting clinical outcomes. Here, we applied a targeted‐capture high‐throughput sequencing approach to profile ctDNA at various disease milestones and assessed its predictive value in patients with early‐stage and locally advanced NSCLC. We prospectively enrolled 33 consecutive patients with stage IA to IIIB NSCLC undergoing curative‐intent tumor resection (median follow‐up: 26.2 months). From 21 patients, we serially collected 96 plasma samples before surgery, during surgery, 1–2 weeks postsurgery, and during follow‐up. Deep next‐generation sequencing using unique molecular identifiers was performed to identify and quantify tumor‐specific mutations in ctDNA. Twelve patients (57%) had detectable mutations in ctDNA before tumor resection. Both ctDNA detection rates and ctDNA concentrations were significantly higher in plasma obtained during surgery compared with presurgical specimens (57% versus 19% ctDNA detection rate, and 12.47 versus 6.64 ng·mL −1 , respectively). Four patients (19%) remained ctDNA‐positive at 1–2 weeks after surgery, with all of them (100%) experiencing disease progression at later time points. In contrast, only 4 out of 12 ctDNA‐negative patients (33%) after surgery experienced relapse during follow‐up. Positive ctDNA in early postoperative plasma samples was associated with shorter progression‐free survival ( P = 0.013) and overall survival ( P = 0.004). Our findings suggest that, in early‐stage and locally advanced NSCLC, intraoperative plasma sampling results in high ctDNA detection rates and that ctDNA positivity early after resection identifies patients at risk for relapse.
- Open Access
- 1 June 2021
- Published by Elsevier in EBioMedicine
- Vol. 68, 103396
Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach
- 1 June 2021
- Published by Elsevier in EBioMedicine
- Vol. 68, 103396
Open AccessQuantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach
- Open Access
- 8 November 2018
- Published by Wiley in Transboundary and Emerging Diseases
- Vol. 66 (1) , 552-561
Identification of a novel clade of group A rotaviruses in fatally diseased domestic pigeons in Europe
Rotaviruses are well‐known causative agents of enteric disorders in humans and other mammals, but little is known about their virulence and pathogenic role in pigeons and other birds. Starting in summer 2017, a series of outbreaks of an acute disease with high mortalities was reported in domestic pigeons in Germany, Belgium and Denmark. The clinical picture was characterized by diarrhea, vomiting, hepatic necrosis, and sudden fatalities. From these severe outbreaks, we discovered several previously unknown group A rotavirus (RVA) lineages of genotype G18P[17]‐I4‐R4‐C4‐M4‐A4‐T4‐N4‐E19‐H4, which were closely related but not identical to an RVA variant identified in cases of fatal hepatic necrosis in Australian pigeon lofts in 2016. Retrospective analysis demonstrated that the predecessors of the highly virulent variants have circulated in Europe since at least 2010. Our data indicate that reassortment and intercontinental spread has led to the emergence of novel RVA variants, which may constitute a major threat to animal welfare and health of domestic pigeon populations worldwide.
- 8 November 2018
- Published by Wiley in Transboundary and Emerging Diseases
- Vol. 66 (1) , 552-561
Open AccessIdentification of a novel clade of group A rotaviruses in fatally diseased domestic pigeons in Europe
Rotaviruses are well‐known causative agents of enteric disorders in humans and other mammals, but little is known about their virulence and pathogenic role in pigeons and other birds. Starting in summer 2017, a series of outbreaks of an acute disease with high mortalities was reported in domestic pigeons in Germany, Belgium and Denmark. The clinical picture was characterized by diarrhea, vomiting, hepatic necrosis, and sudden fatalities. From these severe outbreaks, we discovered several previously unknown group A rotavirus (RVA) lineages of genotype G18P[17]‐I4‐R4‐C4‐M4‐A4‐T4‐N4‐E19‐H4, which were closely related but not identical to an RVA variant identified in cases of fatal hepatic necrosis in Australian pigeon lofts in 2016. Retrospective analysis demonstrated that the predecessors of the highly virulent variants have circulated in Europe since at least 2010. Our data indicate that reassortment and intercontinental spread has led to the emergence of novel RVA variants, which may constitute a major threat to animal welfare and health of domestic pigeon populations worldwide.
- Open Access
- 9 February 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (10) , 17164-17190
ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer
ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer
- 9 February 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (10) , 17164-17190
Open AccessATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer
ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer